BioLineRx Ltd.
شراء
تم تحديثه

BLRX-BREAKOUT-UPDATE

389
BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

لقطة

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB






ملاحظة
As expected, a very strong rally today!
ملاحظة
لقطة
ملاحظة
We got a big runway...
ملاحظة
Reminder this is a WEEKLY chart...

Meaning this move is far from over...
ملاحظة
لقطة
ملاحظة
Buckle up!
ملاحظة
لقطة
ملاحظة
Target $2.24 (Sell Half)

Trade Price: 1.049
ملاحظة
لقطة
ملاحظة
لقطة
ملاحظة
Bull Flag
ملاحظة
BLRX will rally again tomorrow.
ملاحظة
لقطة
ملاحظة
BLRX is about to rally again...
ملاحظة
BLRX continued to consolidate today.

Staying the course...
ملاحظة
لقطة
ملاحظة
لقطة
ملاحظة
Near-Term Target: $2.13
ملاحظة
لقطة
ملاحظة
Primary Wave 1 Complete
ملاحظة
لقطة
ملاحظة
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
ملاحظة
لقطة
ملاحظة
لقطة
ملاحظة
Breakout Imminent
ملاحظة
لقطة

إخلاء المسؤولية

لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.